Zipalertinib with chemo for stage II-IIIB lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted drug (zipalertinib) combined with standard chemotherapy before surgery for non-small cell lung cancer that has specific EGFR mutations. It may help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC).
- Your cancer must be stage II, IIIA, or IIIB (N2) and your doctor thinks it can be removed with surgery.
- Your tumor must have a specific EGFR mutation (like EGFR exon 20 insertion or certain uncommon EGFR changes).
- You cannot have had any prior chemotherapy or other drugs for lung cancer.
- You must be in good overall health (able to perform daily activities) and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
This trial tests a new drug called zongertinib combined with chemotherapy, with or without pembrolizumab (an immunotherapy), for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see how safe and well-tolerated the combination is.
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
Hear when a new Lung Non-Squamous Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.